<DOC>
	<DOCNO>NCT01197066</DOCNO>
	<brief_summary>This phase â…¢ multicenter , open-label , follow-up study , assess safety efficacy certolizumab pegol ( CZP ) additional medication methotrexate ( MTX ) , patient active rheumatoid arthritis ( RA ) participate Study ( Protocol ) # 101-KOA-0801i .</brief_summary>
	<brief_title>Open-label , Extension Study CDP870 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Failed achieve ACR20 response Week 12 Study 101KOA0801i complete entire Study 101KOA0801i Week 24 Have clear chest Xray Entry visit Negative urine pregnancy test Entry Continue treatment methotrexate Any inflammatory arthritis ( e.g. , psoriatic arthritis , ankylose spondylitis reactive arthritis ) Secondary , noninflammatory type arthritis ( eg , osteoarthritis , fibromyalgia ) At study entry take prohibited medication detail Study ( Protocol ) # 101KOA0801i NYHA ( New York Heart Association ) Class III IV congestive heart failure Current history tuberculosis History chronic infection , recent serious lifethreatening infection current sign symptom may indicate infection ( e.g. , fever , cough ) History lymphoproliferative disorder include lymphoma sign symptom suggest lymphoproliferative disease High risk infection Female breast feeding , pregnant plan become pregnant trial 12 week follow last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>